Heike Y, Tsuruo T
Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
Cytotechnology. 1993;12(1-3):91-107. doi: 10.1007/BF00744659.
Multidrug resistance (MDR) is a major problem in cancer chemotherapy. As P-glycoprotein is the key molecule in MDR, many investigators have constructed anti-P-glycoprotein monoclonal antibodies (MAbs). Those antibodies, including MRK16 and C219, were used for elucidation of the mechanism of MDR and for overcoming of MDR. This article describes the characterization of the antibodies against the P-glycoprotein and other proteins of multidrug-resistant tumor cells, and discusses the therapeutic implication of the antibodies.
多药耐药性（MDR）是癌症化疗中的一个主要问题。由于P-糖蛋白是多药耐药性中的关键分子，许多研究人员构建了抗P-糖蛋白单克隆抗体（MAb）。这些抗体，包括MRK16和C219，被用于阐明多药耐药性的机制以及克服多药耐药性。本文描述了针对多药耐药肿瘤细胞的P-糖蛋白和其他蛋白质的抗体的特性，并讨论了这些抗体的治疗意义。
